Navigation Links
Treatment Resistant Tumors Can Be Targeted Better Using Botox

Botox, commonly used for cosmetic treatment may play an important role in enhancing the outcome of chemotherapy and radiotherapy, employed in cancer treatment. // Botox is a derivative of Botulinum toxin, a naturally occurring chemical known to cause intestinal poisoning.

The toxin has numerous clinical applications such as relieving facial spasms, strabismus and treating muscle hyperactivity. The toxin acts by blocking release of acetylcholine and norepinephrine (neurotransmitters).

It is hypothesized that this neurotransmitter release inhibition could inhibit neuromuscular contraction of blood vessels that supply the tumor. This could eventually pave way for enhanced tumor perfusion, allowing effective delivery of cytotoxic drugs and oxygen (improves tumor response to radiotherapy) supplied to the tumor.

To verify the above hypothesis, Dr. Bernard Gallez and his research team injected Botulinum neurotoxin (Type A) into mouse tumors. As expected, the vascular architecture of the tumor opened, destroying the previously resistant cancer cells. The study is the first of its kind to test the use of Botox as an adjuvant in the effective treatment of resistant tumors.

In addition, pre-treatment with Botox delayed further growth of the tumor and promoted apoptosis, that could enhance the clinical outcome of cancer treatment. Based on further research in the same direction, it might even be possible to overcome drug resistance or reduce standard radiotherapy and chemotherapy dosages, thereby eliminating the associated side effects.

Until now, much of cancer treatment has been focused towards starving the tumor of its blood supply. This new approach, targeted at enhanced blood supply for effective delivery of chemotherapeutic agents and radiation represents a new dimension of cancer research.

'Tumor vasculature is targeted by several advanced anti-cancer approaches that may appear contradic tory. Anti-angiogenesis and anti-vascular targeting are methods aimed at destroying the vessels that feed tumors, thereby depriving them of oxygen and nutrients. In contrast, pro-vascular approaches increase tumor perfusion and oxygenation temporarily,' concluded Dr. Gallez.


'"/>




Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/10/2019)... ... January 10, 2019 , ... ... it has partnered with MD101, a regulatory consulting company that serves the medical ... expertise in servicing companies in the medical device and healthcare industries. Based in ...
(Date:1/10/2019)... ... January 10, 2019 , ... ... and Hemp companies, partners with NeuCana Companion to educate dog owners on CBD ... is believed to help calm pain and anxiety related ailments by supporting a ...
(Date:1/8/2019)... ... January 08, 2019 , ... Pentec ... have Norepinephrine in their patent-pending vial-based configuration, Snap-N-Go®, available to order from ... not commercially available) deliver a precise dose when introduced into a diluent ...
(Date:1/7/2019)... ... 07, 2019 , ... byte is thrilled to announce a ... and physical health across the nation. byte is an at-home invisible aligner system ... straighter smile being treated by leading orthodontists and the latest technology that reduces ...
(Date:1/7/2019)... IRVINE, Calif. (PRWEB) , ... January 07, 2019 ... ... a strategic investment in support of DecisionOne Dental Partners based in Schaumburg, Illinois. ... neighboring states. DecisionOne Dental Partners management will continue to lead and operate ...
Breaking Medicine News(10 mins):
(Date:1/15/2019)... ... 2019 , ... HMP, a leader in healthcare events and ... Course (WCPC), the leading comprehensive wound care training program. Based upon the ongoing ... be expanding its course to 12 cities nationwide, including San Francisco, Philadelphia, Nashville, ...
(Date:1/15/2019)... ... January 15, 2019 , ... MDsyncNET ... faith-based nonprofit health system in North Texas, deployed MDsyncNET’s physician on-call scheduling ... CEO Brad Goldsmith, “We’re committed to providing Texas Health Resources with the ...
(Date:1/14/2019)... ... January 14, 2019 , ... USpharma Ltd announced today ... U.S. market. Bayer Consumer Care AG and its affiliates (collectively “Bayer”) have ... to USpharma. Since first being introduced in 1950, Cushion Grip was consistently ...
Breaking Medicine Technology: